Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARA: Nivolumab and Ipilimumab in Renal Cell Carcinoma
NCT05215470Phase 2Active, not recruiting
- Sponsor
- Hospital das Clínicas de Ribeirão Preto
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in renal cell carcinoma (RCC), sponsored by Hospital das Clínicas de Ribeirão Preto. Started Jan 2022; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05215470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215470.